Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer

Trial Profile

Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Sep 2017 Primary endpoint (Percentage of subjects with detectable circulating T cells after treatment) has not been met, according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 26 Sep 2017 Results assessing effects of ipilimumab when added to neoadjuvant chemotherapy (paclitaxel + carboplatin + cisplatin) on levels of detectable circulating T cells with specificities against tumour-associated antigens (TAA) in patients with treatment-naive stage IB or II non-small cell lung cancer, were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top